Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

    June 2026 in “ JEADV Clinical Practice
    Marco Rubatto, Eleonora Bongiovanni, Veronica Arese, Michela Milanesio, Alessia Reali, Massimo Chiarpenello, Gianmauro Numico, Marcella Occelli
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Studysummary In this case report, a 77-year-old woman developed alopecia areata after discontinuing cemiplimab treatment for metastatic cutaneous squamous cell carcinoma, suggesting an immune-related adverse effect potentially linked to systemic immune activation.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    5 / 5 results